Loading…
Leading contract research and manufacturing organization (CRO/CDMO) providing drug discovery and development services to global pharma.
Leading contract research and manufacturing organization (CRO/CDMO) providing drug discovery and development services to global pharma.
Is paid for services rather than for drugs: chemists billed by headcount for discovery work, and per project or batch for development and manufacturing. Clients are drugmakers that keep ownership of what is made, and US and European clients provide most of the revenue. Founder Lou Boliang is chairman.
In one line: China's WuXi AppTec/Catalent hybrid.
Moat: narrow (scale, customer qualification, process know-how). Established global pharma-client relationships and integrated discovery-to-manufacturing service scale.
Headquarters: Beijing, China · Founded: 1996 · Employees: 25,088
Size Pharmaron Beijing (300759.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $11.3B, the 221st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥45.89 on 6 Nov 2026.
Performance Over six months the shares gained 56.6%, against +3.8% for the median peer and -16.4% for the China market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 18.2% over the last twelve months (peer median +13.8%); the operating margin is 14.4% (peer median 17.0%).
Valuation It trades at 42.3× forward earnings against a peer median of 30.9× (7th most expensive of 18).
Capital Return on invested capital runs 1.3 points above its cost of capital (10.3% WACC).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥16.0B | CN¥14.1B | CN¥12.3B | CN¥11.5B | CN¥10.3B |
| Revenue growth | — | +15% | +7% | +12% | — |
| Gross profit | CN¥6.24B | CN¥4.60B | CN¥4.15B | CN¥3.86B | CN¥3.56B |
| EBITDA | n/a | CN¥3.32B | CN¥2.86B | CN¥2.66B | CN¥2.43B |
| Net income | CN¥1.77B | CN¥1.66B | CN¥1.79B | CN¥1.60B | CN¥1.37B |
| Free cash flow | -CN¥202M | CN¥621M | CN¥584M | -CN¥62.3M | -CN¥746M |
| Capital expenditure | CN¥2.97B | CN¥2.67B | CN¥2.04B | CN¥2.87B | CN¥2.95B |
| Total debt | CN¥7.47B | CN¥7.04B | CN¥5.98B | CN¥9.70B | CN¥6.14B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Pharmaron Beijing 300759.SZ | $11.3B | +57% | +18% | 14% | 42.3× | n/a |
| Wuxi Apptec 2359.HK | $66.3B | +40% | +38% | 44% | 20.4× | 8.7% |
| Charles River Laboratories CRL | $16.1B | +90% | -1% | 15% | 26.6× | 25.3% |
| Lonza LONN.SW | $55.4B | +39% | -11% | 25% | 36.1× | 15.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300759.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.9% | +4.2% | 10th highest of 21 |
| 6-month return | +56.6% | +3.8% | 2nd highest of 21 |
| Distance from 52-week high | -14.3% | -10.3% | 9th lowest of 21 |
| Revenue growth (TTM) | +18.2% | +13.8% | 9th highest of 20 |
| Operating margin | 14.4% | 17.0% | 10th lowest of 20 |
| Forward P/E | 42.3× | 30.9× | 7th most expensive of 18 |
| ROIC minus cost of capital | +1.3 pp | +1.6 pp | 9th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Pharmaron Beijing 300759.SZ | China | $11.3B | +57% | +18% | 14% | 42.3× | n/a | n/a |
| Repligen RGEN | United States | $11.1B | +41% | +14% | 9% | 71.3× | 56.4% | +15.0% |
| Mankind Pharma MANKIND.NS | India | $11.1B | +7% | +13% | 21% | 43.2× | 27.6% | +18.1% |
| Dr. Reddy's Laboratories DRREDDY.NS | India | $12.1B | +5% | -4% | 9% | 31.8× | 30.1% | +12.1% |
| Zhangzhou Pientzehuang Pharmaceutical 600436.SS | China | $12.3B | -5% | -19% | 19% | 42.1× | 25.8% | +6.8% |
| Recordati REC.MI | Italy | $12.3B | +3% | +9% | 30% | 16.7× | 1.9% | +12.6% |
| Akeso 9926.HK | Hong Kong | $10.2B | -38% | +42% | -25% | n/a | n/a | n/a |
| Zydus Lifesciences ZYDUSLIFE.NS | India | $12.7B | +27% | +24% | 17% | 29.8× | n/a | n/a |
| Sbp 1177.HK | Hong Kong | $12.7B | +4% | +15% | 30% | 18.3× | -5.4% | +5.4% |
| Spyre Therapeutics SYRE | United States | $9.86B | +38% | n/a | n/a | n/a | n/a | n/a |
| Laurus Labs LAURUSLABS.NS | India | $13.3B | +94% | +23% | 24% | 77.0× | 50.9% | +7.3% |
| Madrigal Pharmaceuticals MDGL | United States | $9.28B | -22% | +93% | -11% | 79.5× | n/a | n/a |
| Sichuan Kelun-Biotech Biopharmaceutical 6990.HK | Hong Kong | $13.9B | 0% | +44% | -38% | 1,255.9× | 56.2% | +33.7% |
| TG Therapeutics TGTX | United States | $9.16B | +40% | +76% | 17% | 30.9× | 50.3% | +426.7% |
| ImmunityBio IBRX | United States | $9.15B | +1% | +193% | -152% | n/a | n/a | n/a |
| Yunnan Baiyao 000538.SZ | China | $14.7B | +4% | +5% | 11% | 18.0× | -0.5% | +4.7% |
| Shanghai Fosun Pharmaceutical (Group) 600196.SS | China | $8.70B | -5% | +8% | 6% | 17.0× | 4.1% | +6.6% |
| Ipsen IPN.PA | France | $14.7B | -4% | +14% | 30% | 10.9× | -7.3% | +7.2% |
| Protagonist Therapeutics PTGX | United States | $8.54B | +33% | +35% | 21% | 48.4× | 47.5% | +10.0% |
| Jazz Pharmaceuticals Public JAZZ | United States | $15.1B | +4% | +13% | 25% | 8.9× | -3.9% | +12.5% |
| Shanghai Pharmaceuticals 2607.HK | Hong Kong | $8.48B | -7% | +9% | 3% | 6.6× | -10.3% | +7.4% |